



## Vicore Pharma has been approved for listing on Nasdaq Stockholm

Gothenburg, September 11, 2019 – Nasdaq Stockholm’s listing committee has approved Vicore Pharma Holding AB (publ)’s (“Vicore”) application to be listed on Nasdaq Stockholm’s main market, subject to customary conditions. The last day of trading on Nasdaq First North Growth Market is expected to be Thursday September 26, 2019 and the first day of trading on Nasdaq Stockholm is expected to be Friday September 27, 2019.

The shares will be traded in the Small Cap segment under the same ticker (VICO) and with the same ISIN code (SE0007577895) as before. No new shares will be issued in connection with the listing. Shareholders of Vicore do not need to take any action in connection with the listing on Nasdaq Stockholm or the delisting from Nasdaq First North Growth Market.

“The up-listing to Nasdaq Stockholm’s main market is a significant step in our long-term plan to develop Vicore. The aim is to further increase the attractiveness of the Vicore share through increased liquidity as the addressable investor base grows significantly”, says Carl-Johan Dalsgaard, CEO of Vicore Pharma.

### Prospectus

Vicore has prepared a prospectus in connection with the admission to trading of Vicore’s shares on Nasdaq Stockholm. The prospectus is expected to be approved and registered by the Swedish Financial Supervisory Authority and published on Vicore’s website on, or about, September 16, 2019.

### Advisors

Advokatfirman Vinge has been engaged as legal advisor in connection with the listing on Nasdaq Stockholm.

### For further information, please contact:

Carl-Johan Dalsgaard, CEO, tel: +46 (0)70 975 98 63, [carl-johan.dalsgaard@vicorepharma.com](mailto:carl-johan.dalsgaard@vicorepharma.com)

Hans Jeppsson, CFO, tel: +46 (0)70-553 14 65, [hans.jeppsson@vicorepharma.com](mailto:hans.jeppsson@vicorepharma.com)

*This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact persons set out above, at 11.45 CEST on September 11, 2019.*

### About Vicore Pharma Holding AB (publ)

Vicore Pharma is a Swedish rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs, VP01 and VP02.

VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”) and diffuse systemic sclerosis (“dSSc”). VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which has a significant high unmet need. The VP01 Phase IIa studies in IPF and dSSc patients are expected to be initiated during the second half of 2019. VP02 is entering a phase of optimization of formulation before local tolerability studies will commence. The first clinical studies with VP02 are expected to start in 2020.

The company’s share (VICO) is listed for trading on Nasdaq First North Growth Market in Stockholm. The company’s certified adviser is Erik Penser Bank, telephone: +46 8 463 83 00, e-mail: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se). For more information, see [www.vicorepharma.com](http://www.vicorepharma.com)